{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chuntova P"],"funding":["NCI NIH HHS","NINDS NIH HHS"],"pagination":["e004644"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9174833"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(5)"],"pubmed_abstract":["<h4>Background</h4>Long-term prognosis of WHO grade II, isocitrate dehydrogenase (IDH)-mutated low-grade glioma (LGG) is poor due to high risks of recurrence and malignant transformation into high-grade glioma. Immunotherapy strategies are attractive given the relatively intact immune system of patients with LGG and the slow tumor growth rate. However, accumulation of the oncometabolite D-2-hydroxyglutarate (D-2HG) in IDH-mutated gliomas leads to suppression of inflammatory pathways in the tumor microenvironment, thereby contributing to the 'cold' tumor phenotype. Inhibiting D-2HG production presents an opportunity to generate a robust antitumor response following tumor antigen vaccination and immune checkpoint blockade.<h4>Methods</h4>An IDH1<sup>R132H</sup> glioma model was created in sy"],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma."],"pmcid":["PMC9174833"],"funding_grant_id":["R01 CA222965","R35 NS105068","T32 CA151022"],"pubmed_authors":["Mende AL","Okada H","Hudson C","Tron AE","Narayanaswamy R","Nejo T","Yamamichi A","Diebold D","Montoya M","Lu M","Ronseaux S","Chuntova P","Nicolay B","Downey KM","Chen T","Hyer ML"],"additional_accession":[]},"is_claimable":false,"name":"Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma.","description":"<h4>Background</h4>Long-term prognosis of WHO grade II, isocitrate dehydrogenase (IDH)-mutated low-grade glioma (LGG) is poor due to high risks of recurrence and malignant transformation into high-grade glioma. Immunotherapy strategies are attractive given the relatively intact immune system of patients with LGG and the slow tumor growth rate. However, accumulation of the oncometabolite D-2-hydroxyglutarate (D-2HG) in IDH-mutated gliomas leads to suppression of inflammatory pathways in the tumor microenvironment, thereby contributing to the 'cold' tumor phenotype. Inhibiting D-2HG production presents an opportunity to generate a robust antitumor response following tumor antigen vaccination and immune checkpoint blockade.<h4>Methods</h4>An IDH1<sup>R132H</sup> glioma model was created in sy","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2026-06-15T06:00:56.56Z","creation":"2025-04-05T23:17:13.715Z"},"accession":"S-EPMC9174833","cross_references":{"pubmed":["35606087"],"doi":["10.1136/jitc-2022-004644"]}}